Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MorphoSys Takes $252.1m Impairment Charge As It Slims Down R&D

Executive Summary

The company will close down early-stage research programs brought under its wing through last year’s acquisition of Constellation Pharmaceuticals.

You may also be interested in...



As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal

The deal will help MorphoSys focus on lifting lackluster Monjuvi sales, and on bringing its promising myelofibrosis candidate pelabresib to market.

MorphoSys Hits Refresh Button On Pipeline With Constellation Buy

The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.

BioMarin Rolls Up Sleeves To Prepare For Roctavian’s EU Debut

The company plans to start in Germany with an outcomes-based payment model. But while a US FDA nod seems likely, analysts have been more cautious about calling US approval a done deal.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146043

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel